2023 | Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial | Zeidan, Amer M; Ando, Kiyoshi; Rauzy, Odile; Turgut, Mehmet; Wang, Ming-Chung; Cairoli, Roberto; HSIN-AN HOU ; Kwong, Yok-Lam; Arnan, Montserrat; Meers, Stef; Pullarkat, Vinod; Santini, Valeria; Malek, Kamel; Kiertsman, Flavia; Niolat, Julie; Ramos, Pedro Marques; Menssen, Hans D; Fenaux, Pierre; Miyazaki, Yasushi; Platzbecker, Uwe | The Lancet. Haematology | 3 | 0 | |